The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets

Vaccine

Volumn 30, Issue 15, 2012, Pages 2516-2522

  Chen, Zhongying ^a   Kim, Lomi ^a   Subbarao, Kanta ^b   Jin, Hong ^a  

^a MEDIMMUNE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Anti neuraminidase antibody response; Cross reactivity; Ferret; Influenza virus; Live attenuated influenza vaccine; Neuraminidase inhibition assay

Indexed keywords

AMINO ACID; ENZYME ANTIBODY; INFLUENZA VACCINE; NEURAMINIDASE ANTIBODY; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FERRET; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; FEMALE; FERRETS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MODELS, MOLECULAR; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; PHYLOGENY; REASSORTANT VIRUSES; VACCINES, ATTENUATED;

EID: 84862777184     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.090     Document Type: Article

References (41)

1. Colman P.M. Neuraminidase enzyme and antigen. The influenza viruses 1989, 175-218. Plenum Press, New York. R. Krug (Ed.).
2. Lamb R.A., Krug R.M. Orthomyxoviridae: the viruses and their replication. Fields virology 2001, 1487-1531. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
3. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., Klenk H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004, 78(22):12665-12667.
4. Mitnaul L.J., Matrosovich M.N., Castrucci M.R., Tuzikov A.B., Bovin N.V., Kobasa D., et al. Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J Virol 2000, 74(13):6015-6020.
5. Wagner R., Matrosovich M.N., Klenk H.D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 2002, 12(3):159-166.
6. Kilbourne E.D., Laver W.G., Schulman J.L., Webster R.G. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 1968, 2(4):281-288.
7. Schulman J.L., Khakpour M., Kilbourne E.D. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968, 2(8):778-786.
8. Johansson B.E., Bucher D.J., Kilbourne E.D. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989, 63(3):1239-1246.
9. Murphy B.R., Kasel J.A., Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972, 286:1329-1332.
10. Couch R.B., Kasel J.A., Gerin J.L., Schulman J.L., Kilbourne E.D. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974, 129(4):411-420.
11. Ogra P.L., Chow T., Beutner K.R., Rubi E., Strussenberg J., DeMello S., et al. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. J Infect Dis 1977, 135(4):499-506.
12. Beutner K.R., Chow T., Rubi E., Strussenberg J., Clement J., Ogra P.L. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. Infect Dis 1979, 140(6):844-850.
13. Deroo T., Jou W.M., Fiers W. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 1996, 14(6):561-569.
14. Kilbourne E.D., Pokorny B.A., Johansson B.E., Brett I., Milev Y., Matthews J.T. Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis 2004, 189(3):459-461.
15. Martinet W., Saelens X., Deroo T., Neirynck S., Contreras R., Min Jou W., et al. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur J Biochem 1997, 247(1):332-338.
16. Chen Z., Matsuo K., Asanuma H., Takahashi H., Iwasaki T., Suzuki Y., et al. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine 1999, 17(7-8):653-659.
17. Bosch B.J., Bodewes R., de Vries R.P., Kreijtz J.H., Bartelink W., van Amerongen G., et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J Virol 2010, 84(19):10366-10374.
18. Johansson B.E. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 1999, 17(15-16):2073-2080.
19. Sylte M.J., Suarez D.L. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol 2009, 333:227-241.
20. Sandbulte M.R., Gao J., Straight T.M., Eichelberger M.C. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir Viruses 2009, 3(5):233-240.
21. Hassantoufighi A., Zhang H., Sandbulte M., Gao J., Manischewitz J., King L., et al. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 2010, 28(3):790-797.
22. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000, 97(11):6108-6113.
23. Jin H., Lu B., Zhou H., Ma C., Zhao J., Yang C.F., et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003, 306(1):18-24.
24. Suguitan A.L.J., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006, 3(9):e360.
25. Chen Z., Wang W., Zhou H., Suguitan A.L.J., Shambaugh C., Kim L., et al. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010, 84(1):44-51.
26. Chen Z., Santos C., Aspelund A., Gillim-Ross L., Jin H., Kemble G., et al. Evaluation of live attenuated influenza a virus H6 vaccines in mice and ferrets. J Virol 2009, 83(1):65-72.
27. Jahiel R.I., Kilbourne E.D. Reduction in plaque size and reduction in plaque number as differing indices of influenza virus-antibody reactions. J Bacteriol 1966, 92(5):1521-1534.
28. Li Q., Qi J., Zhang W., Vavricka C.J., Shi Y., Wei J., et al. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 2010, 17(10):1266-1268.
29. Cate T.R., Rayford Y., Niño D., Winokur P., Brady R., Belshe R., et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28(9):2076-2079.
30. Clements M.L., Tierney E.L., Murphy B.R. Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccine. J Clin Microbiol 1985, 21(6):997-999.
31. Powers D.C., Kilbourne E.D., Johansson B.E. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin Diagn Lab Immunol 1996, 3(5):511-516.
32. Marcelin G., Bland H.M., Negovetich N.J., Sandbulte M.R., Ellebedy A.H., Webb A.D., et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J Infect Dis 2010, 202(11):1634-1638.
33. Johansson B.E., Pokorny B.A., Tiso V.A. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 2002, 20(11-12):1670-1674.
34. Lambré C.R., Terzidis H., Greffard A., Webster R.G. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 1990, 135(1-2):49-57.
35. Matsuoka Y., Swayne D.E., Thomas C., Rameix-Welti M., Naffakh N., Warnes C., et al. Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice. J Virol 2009, 83(9):4704-4708.
36. Wang W., Lu B., Zhou H., Suguitan A.L.J., Cheng X., Subbarao K., et al. Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets. J Virol 2010, 84(13):6570-6577.
37. Zhou H., Yu Z., Hu Y., Tu J., Zou W., Peng Y., et al. The special neuraminidase stalk-motif responsible for increased virulence and pathogenesis of H5N1 influenza A virus. PLoS One 2009, 4(7):e6277.
38. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(5937):197-201.
39. Sandbulte M.R., Jimenez G.S., Boon A.C., Smith L.R., Treanor J.J., Webby R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007, 4(2):e59.
40. Ambrose C.S., Luke C., Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respir Viruses 2008, 2(6):193-202.
41. Kilbourne E.D., Johansson B.E., Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci USA 1990, 87(2):786-790.